Our CEO has just exercised 224,000 options to buy more stock.
The exercise prices are low but she has nevertheless coughed up hard cash to increase her shareholding.
It will be interesting to see if she holds onto them or realises the gain at the current market price.
In addition, she has been granted two tranches of 400,000 options exerciseable at around 75c over the next five years.
One tranche vests on the basis that the CEO is still in the job; and the other tranche vest on the basis of having delivered specific KPI's - which all seems pretty reasonable to me.
This increases the CEO's exposure and leverage to further price gains - which is not a bad thing.
It is noteworthy that the exercise price on the options is nearly 60% above the current share price.
It is also about half of what Shaw Partners value the company at - so you be the judge on whether the strike price is reasonable or not.
The clock is still ticking on the oncology asset sales process and market chatter suggests that we should hear something by 30th June.
I sure hope those rumors are right and not just hot air from wishful thinkers!
Current share price pull-back is all good and healthy given the macro jitters and the nut-job in the White House.
GLTA.
Add to My Watchlist
What is My Watchlist?